Filter sub products categories alphabetically
Adult AIDS patients with retinal cytomegalovirus infections are treated with valganciclovir. In recipients of organ transplants from CMV-infected donors, it serves as a preventive measure against CMV infection. A viral infection of the retina brought on by cytomegalovirus is known as CMV retinitis. It functions by changing in the body into ganciclovir, which inhibits the growth of viruses. This aids in the infection's management. In 2001, the FDA authorized valganciclovir.
BRAND NAMES
Valcyte: It includes the active component, valganciclovir. It is available in tablet and oral solution form and is used to treat and prevent illness caused by the CMV virus in persons who have undergone organ transplantation.
MECHANISM OF ACTION
Valganciclovir is a prodrug that is quickly transformed to ganciclovir following oral administration. It is a guanosine analogue that is activated by viral thymidine kinase to monophosphate. The triphosphate analogue of ganciclovir inhibits viral DNA polymerase activity by blocking DNA chain elongation. It results in chain termination or the formation of shot, non-infectious viral DNA fragments.
PHARAMCOKINETICS
ABSORPTION
Valganciclovir is efficiently absorbed from the gastrointestinal system, with valganociclovir tablets having an absolute bioavailability of roughly 60%.
DISTRIBUTION
The mean volume of distribution of valganciclovir is 0.703±0.134L/kg.
METABOSLIM
It is rapidly metabolized in the intestinal wall and liver to ganciclovir. No other metabolites have been detected.
EXCRETION
Valganciclovir is eliminated primarily by renal excretion as ganciclovir via glomerular filtration and active tubular secretion.
PHARMACODYNAMICS
Valganciclovir is an antiviral drug that treats cytomegalovirus infections. It functions as a prodrug for ganciclovir since it is the l-valyl ester of the drug. After oral dosing, intestinal and hepatic esterases quickly convert it to ganciclovir. Following this, it is integrated into DNA and cannot be read correctly by DNA polymerase. This stops the elongation of viral DNA.
DOSAGE AND ADMINISTARTION
Valganciclovir is available in both tablet and oral solution forms. It is often consumed with meals once or twice each day.
It is available in tablet form (450mg) and powder for oral solution (50mg/ml).
DRUG INTERACTIONS
Drug interaction of valganciclovir may interact with
Antibiotics – imipenem
Gout medicine – probenecid
Antifungal – amphotericinB
Anti-protozoals – pentamidine
Anti-cancer – vinblastine
Immune-suppressants – tacrolimus
HIV-AIDS – tenofovir and zidovudine
Hepatitis B infection medicine - -adefovir
CONTRAINDICATIONS
It is contraindicated with history of significant hypersensitivity reaction.
SIDE EFFECTS
Side effects of valganciclovir may includes
Serious side effects of valganciclovir may includes
OVERDOSE
Symptoms of overdose may includes
TOXICITY
Valganciclovir overdose is also likely to cause greater renal damage.